Xenetic Biosciences (XBIO) Interest Expenses (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Interest Expenses came in at $39.9 million in Q1 2026, down 3.62% YoY from $41.4 million in Q1 2025, and down 4.32% on a QoQ basis from $41.7 million in Q3 2025.
Xenetic Biosciences (XBIO) Interest Expenses (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Interest Expenses data on file, last reported at $39.9 million in Q1 2026.
- Quarterly Interest Expenses fell 3.62% year-over-year to $39.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.9 million (down 3.62% YoY) and the FY2025 annual result came in at $39.8 million, down 3.23% from the prior year.
- Interest Expenses retreated to $39.9 million in Q1 2026, from $41.7 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $41.7 million in Q3 2025 to a low of $27043.0 in Q4 2022.
- A 5-year average of $35.7 million and a median of $39.6 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 191.32% — and 2026, when it decreased 3.62%.
- Tracing XBIO's Interest Expenses over 5 years: stood at $27043.0 in 2022, then jumped by 144854.33% to $39.2 million in 2023, then grew by 3.57% to $40.6 million in 2024, then rose by 2.71% to $41.7 million in 2025, then slipped by 4.32% to $39.9 million in 2026.
- The last three Interest Expenses figures came in at $39.9 million (Q1 2026), $41.7 million (Q3 2025), and $41.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.20 Mn |
| Jun 30, 2026 | 40.20 Mn |
| Mar 31, 2026 | 39.90 Mn |
| Mar 31, 2026 | 39.90 Mn |
| Sep 30, 2025 | 41.70 Mn |
| Sep 30, 2025 | 41.70 Mn |
| Jun 30, 2025 | 41.60 Mn |
| Jun 30, 2025 | 41.60 Mn |
| Mar 31, 2025 | 41.40 Mn |
| Mar 31, 2025 | 41.40 Mn |
| Sep 30, 2024 | 40.60 Mn |
| Sep 30, 2024 | 40.60 Mn |
| Jun 30, 2024 | 40.40 Mn |
| Jun 30, 2024 | 40.40 Mn |
| Mar 31, 2024 | 40.10 Mn |
| Mar 31, 2024 | 40.10 Mn |
| Sep 30, 2023 | 39.20 Mn |
| Sep 30, 2023 | 39.20 Mn |
| Jun 30, 2023 | 39.00 Mn |
| Jun 30, 2023 | 39.00 Mn |